183 related articles for article (PubMed ID: 9519354)
1. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Sylvester RJ; Denis L; de Voogt H
Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
[TBL] [Abstract][Full Text] [Related]
2. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ; Studer U; Schröder FH; Klijn JG; de Pauw M; Sylvester R
Eur Urol; 1998; 33(2):152-8. PubMed ID: 9519356
[TBL] [Abstract][Full Text] [Related]
3. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
Denis LJ; Keuppens F; Smith PH; Whelan P; de Moura JL; Newling D; Bono A; Sylvester R
Eur Urol; 1998; 33(2):144-51. PubMed ID: 9519355
[TBL] [Abstract][Full Text] [Related]
4. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
[TBL] [Abstract][Full Text] [Related]
5. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
6. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Keuppens F; Denis L; Smith P; Carvalho AP; Newling D; Bond A; Sylvester R; De Pauw M; Vermeylen K; Ongena P
Cancer; 1990 Sep; 66(5 Suppl):1045-57. PubMed ID: 2144206
[TBL] [Abstract][Full Text] [Related]
7. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Smith PH; Bono A; Calais da Silva F; Debruyne F; Denis L; Robinson P; Sylvester R; Armitage TG
Cancer; 1990 Sep; 66(5 Suppl):1009-16. PubMed ID: 2144203
[TBL] [Abstract][Full Text] [Related]
8. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Iversen P
Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
[TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
Rosendahl I; Kiebert GM; Curran D; Cole BF; Weeks JC; Denis LJ; Hall RR
Prostate; 1999 Feb; 38(2):100-9. PubMed ID: 9973095
[TBL] [Abstract][Full Text] [Related]
10. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Iversen P; Suciu S; Sylvester R; Christensen I; Denis L
Cancer; 1990 Sep; 66(5 Suppl):1067-73. PubMed ID: 2144208
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
12. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
13. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
[TBL] [Abstract][Full Text] [Related]
14. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
Robinson MR; Smith PH; Richards B; Newling DW; de Pauw M; Sylvester R
Eur Urol; 1995; 28(4):273-83. PubMed ID: 8575493
[TBL] [Abstract][Full Text] [Related]
15. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
[TBL] [Abstract][Full Text] [Related]
16. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
Suciu S; Sylvester R; Iversen P; Christensen I; Denis L
Cancer; 1990 Sep; 66(5 Suppl):1029-34. PubMed ID: 2144205
[TBL] [Abstract][Full Text] [Related]
17. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
de Voogt HJ; Klijn JG; Studer U; Schröder F; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):965-9. PubMed ID: 2149509
[TBL] [Abstract][Full Text] [Related]
18. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
[TBL] [Abstract][Full Text] [Related]
19. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Jurincic-Winkler C; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
Eur Urol; 2000 Feb; 37(2):205-11. PubMed ID: 10705200
[TBL] [Abstract][Full Text] [Related]
20. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Robinson MR; Denis L; Newling DW; Sylvester R; De Pauw M
Cancer; 1990 Sep; 66(5 Suppl):1022-4. PubMed ID: 2144204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
